Address of Corresponding Author

Nephron Physiol 2004;98:p48-p54 (DOI: 10.1159/000080264)

  Key Words

• Calcium oxalate
• Hyperoxaluria
• Lactobacillus
• Nanobacteria
• Nephrolithiasis
• Oxalates
• Oxalobacter formigenes
• Oxaluria
• Urinary calculi
• Urolithiasis

  Abstract

Microorganisms may have a role in the pathogenesis and prevention of kidney stones. The subjects of this review include nanobacteria, Oxalobacter formigenes, and lactic acid bacteria. Not reviewed here is the well-described role of infections of the urinary tract with Proteus species and other urease-producing organisms associated with struvite stone formation. Nanobacteria have been proposed to be very small (0.08-0.5 nm), ubiquitous organisms that could play a role in stone formation. The theory is that nanobacteria can nucleate carbonate apatite on their surfaces and thereby provide the nidus for stone formation. However, their existence remains uncertain and many investigators are openly skeptical. Recent investigations suggest that they are artifacts, and not actually living organisms, but their proponents continue to study them. O. formigenes is an obligate anaerobe which may be important in the prevention of stone formation. Its sole substrate for generation of ATP is oxalate. It may thereby metabolize its human host's dietary oxalate and diminish intestinal absorption and subsequent urinary excretion of oxalate. There is evidence that the organism's absence, perhaps sometimes due to courses of antibiotics, may be a cause of hyperoxaluria and stone formation. In early investigations, patients not colonized with the organism can be recolonized. Urinary oxalate can be diminished by accompanying an oxalate-containing meal with the organism. One study demonstrated that a preparation of lactic acid bacteria successfully reduced urinary oxalate excretion in 6 patients with calcium oxalate stones and hyperoxaluria. The mechanism of this effect is uncertain since these bacteria lacked the gene possessed by O. formigenes which codes for that organism's oxalate uptake mechanism. The author is currently completing a small randomized controlled clinical trial with this preparation in calcium stone-forming patients with idiopathic hyperoxaluria.

Copyright © 2004 S. Karger AG, Basel

  Author Contacts

David S. Goldfarb, MD
Nephrology Section/111G, New York DVAMC
423 E. 23 St.
New York, NY 10010 (USA)
Tel. +1 212 686 7500, ext. 3877, Fax +1 212 951 6842, E-Mail david.goldfarb@med.va.gov

  Article Information

Research Support from VSL Pharmaceuticals, Inc.

Number of Print Pages : 7
Number of Figures : 0, Number of Tables : 0, Number of References : 36